Reasons to go for Rezūm steam therapy: an effective and durable outpatient minimally invasive procedure

Arezki, Adel; Sadri, Iman; Couture, Félix; Schwartz, Russell; Nguyen, Donald H.; Zakaria, Ahmed; Roehrborn, Claus G.; McVary, Kevin T.; Zorn, Kevin C.

doi:10.1007/s00345-020-03457-9

Cited by 15 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, NICE reported a cost-effectiveness analysis in the United Kingdom and according to this report, Rezum is cost less than Urolift, TURP and HoLEP [13,27]. The published data of 197 patients from 15 centers in the USA showed an effective sustainable relief of LUTS secondary to BPH up to 4 years' post-Rezum procedure with no reported significant side effects [14].…”

Section: Cost Analysismentioning

confidence: 87%

“…Transrectal ultrasound (TRUS) is advised before the procedure for size evaluation and to determine the number of injections. Additionally, a prostatic nerve block may be done simultaneously [13].…”

Section: Rezum Proceduresmentioning

confidence: 99%

“…The procedural time is dependent on the prostatic urethral length and the size of the median lobe. Bole et al reported that the maximum number of possible injections was 15 injections over 135 s [11,13].…”

Section: Rezum Proceduresmentioning

confidence: 99%

See 2 more Smart Citations

Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article

Higazy

Osman

2021

Int Urol Nephrol

View full text Add to dashboard Cite

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are one of the most common morbidities in elderly men, especially in aging societies. Minimally invasive surgical treatments (MISTs) for BPH have gained an increasing interest in the current time. Rezum system is a novel MIST that uses water vapour-based convective thermal therapy to ablate prostatic tissue. According to our evaluation of the existing literature, Rezum offers a meaningful relief of LUTS with a high safety profile without compromising the sexual activity especially to those who are unfit for surgery or to those who do not desire to continue on lifelong pharmacotherapy.

show abstract

Section: Cost Analysismentioning

confidence: 87%

Section: Rezum Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article

Higazy

Osman

2021

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…Furthermore, this procedure can be done without general anesthesia, which may be favorable for some older patients. It has also been evaluated for costeffectiveness in the USA when compared to long-term follow-up with TURP, which showed Rezum to be comparative in health and financial burden [13,14]. The literature has indicated that while clinical improvement was increased with TURP, due to lower adverse effects with Rezum, an overall reduction in cost is observed [10,14] [15].…”

Section: Discussionmentioning

confidence: 99%

Rezum Therapy for Benign Prostatic Hyperplasia: Dubai’s Initial Experience

Rowaiee¹,

Akhras²,

Lakshmanan³

et al. 2021

Cureus

View full text Add to dashboard Cite

IntroductionSymptomatic benign prostatic hyperplasia (BPH) is a condition that affects middle-aged men, leading to a decreased quality of life secondary to symptoms of difficult urination, urinary frequency, urgency and nocturia. The treatment modalities of this pathology include pharmacologic and invasive interventions, both of which vary in effectiveness and they come with a myriad of side effects. Recent advancements have allowed for the development of Rezum, a minimally invasive and effective approach to treating BPH while maintaining a good safety profile with comparable outcomes to other treatment modalities. MethodsWe retrospectively identified 49 patients with symptomatic BPH who underwent Rezum therapy in one center in Dubai, the United Arab Emirates between January and December 2020. We assessed several parameters related to their condition including prostate volume, pre-operative and post-operative post-void residual (PVR) and peak urinary flow (Qmax) number of treatments given, trial without catheter and mean date of follow-up. Safety and side effects were also assessed. ResultOur sample included symptomatic men with a mean age of 64 (10) who had a mean follow-up time of three months (IQR 2-5.2), median prostatic volume of 58 cc (IQR 44-82) and a mean of (SD 33.9). The initial Qmax and PVR were 7.3 ml/s (IQR 5.5-10.3) and 80.4 cm 3 (IQR 43.4-120.0) respectively, and post-operative Qmax and PVR were 16.3 ml/s (SD 5.7) and 20.7 cm 3 (IQR 16.2-28.2). Post-operatively, we observed a significant increase in Qmax of 8.11 ml/s (p=0.001) post-operatively, a mean decrease of 94.32 cm 3 (p=0.001) in PVR. The favorable outcome parameters in Qmax and PVR demonstrate the efficacy of this procedure. We have also noted that the change in Qmax and PVR does not vary by initial prostate volume. ConclusionIn this report, we aimed to highlight the benefit, efficacy and safety of offering Rezum to patients with symptomatic BPH in a single center in Dubai, reporting on the first United Arab Emirates experience with this novel procedure. This procedure confers the benefit of being minimally invasive, safe and effective, and with lower rates of sexual dysfunction compared to medical therapy or trans-urethral resection of the prostate (TURP). It is associated with similar outcomes to TURP, and an improvement in quality of life, while carrying a low-risk profile. Our experience corresponds with the available literature regarding the efficacy and satisfaction rates of Rezum for BPH patients. We hope that results from this study encourage further investigation into the long-term implications of Rezum, up to five years post-operatively.

show abstract

“…If aquablation comes closest to what technology can achieve in future combined with artificial intelligence, the other aspired technique of today seems to keep the treatment in the hand of the steampunk prone surgeon in 2021. The available data off-site RCT against surgical comparator are explained by the third paper from Kevin Zorn and colleagues [13]. The group around Christian Gratzke [14] is summarising the rationale and evidence for the new MIS, namely iTIND, Urolift and Rezūm besides the shortcomings mentioned by Mark Speakerman in the above-mentioned article on certainty.…”

mentioning

confidence: 99%

TURPxit or not: contemporary management options for benign prostatic obstruction

et al. 2021

View full text Add to dashboard Cite

The idea to the header of this special edition of the World Journal of Urology arose during the campaign for the 2019 election in United Kingdom, in a time of uncertainty on the further course of the European Union and its beloved relative from the isle.This volume is meant to table a motion with regard to the topic of TURPxit. As in Brexit even 2021, it still remains unclear what exactly the TURPxiteers want to leave and want to substitute, furthermore, what the TURPsceptics feel uncomfortable about, and finally, what the remainers want to stay with in the end.This might probably be because the acronym TURP seems to be descriptive but remains uncertain. To stay within the picture, Brexit makes perfectly sense with regard to the TURP template as the UK and Europe do speak of different

show abstract

Reasons to go for Rezūm steam therapy: an effective and durable outpatient minimally invasive procedure

Cited by 15 publications

References 26 publications

Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article

Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article

Rezum Therapy for Benign Prostatic Hyperplasia: Dubai’s Initial Experience

TURPxit or not: contemporary management options for benign prostatic obstruction

Contact Info

Product

Resources

About